"Replicate Bioscience's Breakthrough in Combatting Mono-Causing Virus with srRNA Technology"
Replicate Bioscience, a San Diego startup, has reported positive results from an 84-person clinical trial of its experimental mRNA rabies vaccine, indicating potential for stronger immunity with smaller doses. CEO Nathaniel Wang plans to raise a Series B round based on the data but acknowledges the need for a pharmaceutical or government partner to advance the vaccine into larger studies.